Possible Association between Diabetes and Bisphosphonate-Related Jaw Osteonecrosis

Author:

Khamaisi Mogher1,Regev Eran2,Yarom Noam3,Avni Batia4,Leitersdorf Eran1,Raz Itamar1,Elad Sharon54

Affiliation:

1. Department of Internal Medicine B and the Diabetes Center (M.K., E.L., I.R.), Hebrew University-Hadassah Medical Center, Jerusalem 91120, Israel

2. Department of Oral and Maxillofacial Surgery (E.R.), Hadassah Medical Center, Jerusalem 91120, Israel

3. Department of Oral Pathology and Oral Medicine (N.Y.), The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv 69978, Israel

4. Department of Department of Hematology (B.A., S.E.), Hadassah Medical Center, Jerusalem 91120, Israel

5. Department of Oral Medicine (S.E.), Hebrew University-Hadassah School of Dental Medicine, Hadassah Medical Center, Jerusalem 91120, Israel

Abstract

Abstract Context: Bisphosphonate-related osteonecrosis (BON) of the jaws is a newly identified condition for which the exact mechanism involved in its pathogenesis remains obscure. Objective: The objective of the study was to evaluate whether diabetes mellitus (DM) may be a contributing factor in the development of BON. Design: From 2004 to 2006, 31 patients were diagnosed with BON. The diagnosis of BON was based on the medical and dental history of each patient as well as the observation of clinical signs and symptoms of this pathological process. DM was based on two consecutive fasting blood glucose levels above 7 mmol/liter. Setting: The study was completed in the Hebrew University-Hadassah Hospital referral center. Results: Of the 31 patients with BON, 18 (58%) were found to have DM or impaired fasting glucose. The proportion of diabetic patients was much higher than expected relative to the incidence of DM in the general population (14%) and compared with the proportion of diabetic patients in a control group of oncological patients treated with bisphosphonates and without BON (12%) (P = 0.00003). Conclusions: This finding indicates that DM may be a risk factor for BON and that DM patients treated with bisphosphonates should be carefully monitored. We discuss here the bone metabolic pathways characteristic of DM patients and the way in which these pathways can augment the effects of bisphosphonates.

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Reference20 articles.

1. Osteoporosis;Lindsay;In: Braunwald EFA, Kasper DL, Hauser SL, Long DL, Jameson JL, eds. Harrison’s principles of internal medicine. New York: McGraw-Hill;,2001

2. Bisphosphonates and bone necrosis.;Pogrel;J Oral Maxillofac Surg,2004

3. Osteonecrosis of the jaws associated with cancer chemotherapy.;Wang;J Oral Maxillofac Surg,2003

4. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.;Marx;J Oral Maxillofac Surg,2003

5. Osteonecrosis of the jaw and bisphosphonates.;Woo;N Engl J Med,2005

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3